Medeon Biodesign (6499) — Cash Flow Reinvestment Rate

Latest as of March 2022: 5.77x

Medeon Biodesign (6499) has a Cash Flow Reinvestment Rate of 5.77x as of March 2022, reinvesting NT$350.52 Million (capex NT$41.12 Million plus investments NT$309.40 Million) from operating cash flow of NT$60.74 Million. See Medeon Biodesign (6499) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

5.77x

(Capex + Investments) / Operating CF

Total Reinvested

NT$350.52 Million

Capex + Investments

Operating Cash Flow

NT$60.74 Million

TWD

Capital Expenditures

NT$41.12 Million

TWD

Medeon Biodesign Cash Flow Reinvestment Rate (2018–2018)

Historical reinvestment intensity for Medeon Biodesign across 1 annual periods. For the full cash flow conversion analysis, see Medeon Biodesign cash flow conversion.

Annual Cash Flow Reinvestment Rate for Medeon Biodesign (2018–2018)

Year-by-year capital reinvestment analysis for Medeon Biodesign. See 6499 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2018	0.96x	NT$310.54 Million	NT$322.05 Million	NT$51.14 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow